Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.660
-0.040 (-2.35%)
At close: Apr 28, 2026, 4:00 PM EDT
1.710
+0.050 (3.01%)
After-hours: Apr 28, 2026, 7:48 PM EDT
Ocugen Employees
Ocugen had 116 employees as of December 31, 2025. The number of employees increased by 21 or 22.11% compared to the previous year.
Employees
116
Change (1Y)
21
Growth (1Y)
22.11%
Revenue / Employee
$38,043
Profits / Employee
-$584,879
Market Cap
561.94M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ProKidney | 231 |
| CorMedix | 191 |
| Rigel Pharmaceuticals | 174 |
| Sutro Biopharma | 137 |
| Kyverna Therapeutics | 130 |
| enGene Therapeutics | 82 |
| Prothena Corporation | 67 |
| Tectonic Therapeutic | 60 |
OCGN News
- 5 days ago - Ocugen to Present at April 2026 Investor and Industry Conferences - GlobeNewsWire
- 27 days ago - Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease - GlobeNewsWire
- 5 weeks ago - Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls - Benzinga
- 5 weeks ago - Ocugen Transcript: Study update - Transcripts
- 5 weeks ago - Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 5 weeks ago - Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy - GlobeNewsWire
- 7 weeks ago - Ocugen Earnings Call Transcript: Q4 2025 - Transcripts
- 7 weeks ago - Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire